Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a month.

This story incorporates reporting fromdevdiscourse, WJON and KIMT.Novo Nordisk has settled a lawsuit with Minnesota, agreeing to cap insulin prices at $35 per monthly prescription. This legal resolution addresses the lawsuit initiated by Minnesota Attorney General Keith Ellison,

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

Minnesota announced a third and final settlement Monday in its price-fixing lawsuit against the so-called Big Three manufacturers of insulin, expanding low-cost access to the diabetes drug. Novo Nordisk agreed to cap insulin prices for the next five years so that Minnesotans won’t have to pay any more than $35 for monthly prescriptions.

Minnesotans can expect to pay a lower out-of-pocket cost for insulin.

Minnesota Attorney General Keith Ellison announced a settlement with pharmaceutical company Norvo Nordisk over allegations of inflated insulin prices. The suit was filed in 2018, and in that time Ellison says insulin costs had reached $6,

The settlement means all Minnesotans can purchase insulin from the three biggest insulin manufacturers for just $35 per month.

Minnesota Attorney General Keith Ellison says his office has reached a settlement with Novo Nordisk over high insulin costs.